RARE logo

RARE
Ultragenyx Pharmaceutical Inc

2,851
Mkt Cap
$2.44B
Volume
1.41M
52W High
$42.37
52W Low
$18.29
PE Ratio
-4.24
RARE Fundamentals
Price
$24.77
Prev Close
$24.69
Open
$24.90
50D MA
$22.55
Beta
1.10
Avg. Volume
1.69M
EPS (Annual)
-$5.83
P/B
-29.85
Rev/Employee
$490,882.57
$2,833.80
Loading...
Loading...
News
all
press releases
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at Wall Street Zen
Wall Street Zen raised Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research note on Sunday...
MarketBeat·14h ago
News Placeholder
More News
News Placeholder
Pictet Asset Management Holding SA Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE
Pictet Asset Management Holding SA lowered its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 15.6% during the 4th quarter, according to its most recent disclosure with the...
MarketBeat·2d ago
News Placeholder
Barclays Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00
Barclays cut their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating on the stock in a research report on Wednesday...
MarketBeat·4d ago
News Placeholder
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4d ago
News Placeholder
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eighteen research firms that are currently covering the firm...
MarketBeat·4d ago
News Placeholder
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·5d ago
News Placeholder
Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Tuesday
Ultragenyx Pharmaceutical (NASDAQ:RARE) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-ultragenyx-pharmaceutical-inc-stock...
MarketBeat·5d ago
News Placeholder
Teacher Retirement System of Texas Purchases 327,502 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Teacher Retirement System of Texas boosted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 1,570.9% during the 4th quarter, according to the company in its most recent...
MarketBeat·7d ago
News Placeholder
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Above 50-Day Moving Average - Here's Why
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Crosses Above 50-Day Moving Average - What's Next...
MarketBeat·8d ago
News Placeholder
Ultragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Sell Rating by Wall Street Zen
Wall Street Zen downgraded shares of Ultragenyx Pharmaceutical from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·9d ago
<
1
2
...
>

Latest RARE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.